Study Finds Inconsistent Reimbursement Assessments Across EU Markets
While some modifications in the HTA process for orphan drugs have had some positive impacts, manufacturers still face key hurdles [...]
OptumRx: Rising Orphan Drug Competition Could Lead to Lower Prices
Increased competition in the orphan drug market could ultimately help pull down prices, OptumRx suggests in a new report. According [...]
OptumRx: Payers Should Monitor Three Key Drugs
OptumRx in its latest drug pipeline update recommends payers to keep an eye on risdiplam, viltolarsen and trodelvy, FierceHealthcare reports. [...]
Study: Orphan Drugs Offer ‘Larger Health Gains’ Over Non-Orphan Drugs
A recent study led by Tufts CEVR's James Chambers suggests orphan drugs "offer larger health gains than non-orphan drugs." However, [...]
Advertisement
